Positive leronlimab treatment in critically Ill COVID-19 patient published
On Mar. 23, 2021, CytoDyn announced the publication in the Journal of Translational Autoimmunity ‘Case study of a…
Moderna announced supply agreement with the Philippines for 7 million additional doses of COVID-19 Vaccine Moderna
On Mar. 22, 2021, Moderna announced that the Philippines had secured 7 million additional doses of COVID-19 Vaccine…
Incyte announced results from phase 3 DEVENT study evaluating Jakafi as treatment for patients with COVID-19
On Mar. 18, 2021, Incyte announced results from the Phase 3 DEVENT study evaluating the efficacy and safety…
Twist Bioscience began shipping of synthetic RNA controls for B.1.351 and P.1 variants
On Mar. 15, 2021, Twist Bioscience announced that it had started shipping its new synthetic RNA reference controls,…
ContraFect announced BARDA contract award for up to $868 million for antibiotic-resistant infections
On Mar. 11, 2021, ContraFect announced that it had been awarded a cost-share contract from the Biomedical Advanced…
Innovation Pharma’s COVID-19 drug candidate Brilacidin among top three percent predicted most effective against SARS-CoV-2
On Mar. 10, 2021, Innovation Pharmaceuticals announced that a Machine Learning (Artificial Intelligence) model used to screen 1,482…
AXIM Biotechnologies successfully completed point-of-care clinical trials on rapid COVID-19 antibody test
On Mar. 8, 2021, AXIM Biotechnologies announced that it had successfully completed point-of-care clinical trials on its much…
Moderna announced NDA submitted to import and distribute Moderna’s COVID-19 vaccine candidate in Japan
On Mar. 5, 2021, Moderna announced that Takeda Pharmaceutical submitted a New Drug Application (NDA) to the Government…
Recruitment and enrollment began for Innovation Pharma’s phase 2 clinical trial of Brilacidin for COVID-19
On Mar. 5, 2021, Innovation Pharmaceuticals reported that eight sites were participating in the Company’s international Phase 2…
Pfizer-BioNTech’s COVID-19 vaccine arrived in Rwanda
On Mar. 3, 2021, Pfizer and BioNTech, in partnership with UNICEF, announced the arrival of the first doses…
Altasciences announced phase I research for COVID-19 pneumonia treatment
On Mar. 3, 2021, Altasciences announced support for ReAlta Life Sciences’ Phase I trial to evaluate RLS-0071 for…
NIH invested in next iteration of public-private partnership to advance precision medicine for Alzheimer’s disease
On Mar. 2, 2021, the NIH announced it had launched the next version of the Accelerating Medicines Partnership…
Biotechnology | Disease | FDA | Genomics | Life Science News | Therapeutics
FDA approved targeted treatment for rare Duchenne muscular dystrophy mutation
On Feb. 25, 2021, the FDA granted approval to Sarepta Therapeutics for Amondys 45 (casimersen) injection for the…
NeuroRx announced that ZYESAMI (Aviptadil) had successfully demonstrated accelerated recovery from Covid-19 respiratory failure
On Feb. 24, 2021, NeuroRx, announced that the phase 2b/3 trial of ZYESAMI for the treatment of Respiratory…
Pfizer and BioNTech submited COVID-19 vaccine stability data at standard freezer temperature to the FDA
On Feb. 19, 2021, BioNTech announced the submission of new data to the FDA demonstrating the stability of…
Luminex received BARDA funding to support development and validation of test combining SARS-CoV-2 and Flu/RSV respiratory pane
On Feb. 19, 2021, Luminex announced that it had received $11.3 million in funding from the Biomedical Advanced…
Anixa Biosciences began animal resting of Covid-19 therapeutic candidates
On Feb. 16, 2021, Anixa Biosciences announced that animal testing had commenced with two proprietary compounds that have…
Lonza expanded solid form services for small molecule drugs
On Feb. 16, 2021, Lonza, formerly Bend Research, announced that it was expanding and refining first-in-human services at…
Notch Therapeutics closed $85 million financing to develop pipeline of renewable stem cell-derived cancer immunotherapies
On Feb. 10, 2021, Notch Therapeutics closed $85 Million Series A financing to develop pipeline of renewable stem…
Merck Statement on Ivermectin use During the COVID-19 Pandemic
On Feb. 4, 2021, Merck affirmed its position regarding use of ivermectin during the COVID-19 pandemic, and do…
AXIM Biotechnologies began clinical trials of ImmunoPass rapid diagnostic test with vaccine recipients
On Feb. 3, 2021, AXIM Biotechnologies announced initiation of clinical trials for ImmunoPass, the Companyï¾’s rapid point-of-care test…
NeuroRx initiated phase 2/3 study of inhaled ZYESAMI for severe COVID-19 with UCI Health
On Feb. 3, 2021, RELIEF THERAPEUTICS affirmed that its collaboration partner NeuroRx had initiated a phase 2/3 clinical…
Mateon announced completion of ARTI-19 and publication of positive interim data
On Feb. 2, 2021, Mateon Therapeutics announced that its ARTI-19 trial, evaluating ARTIVeda / PulmoHeal against COVID-19 in…
Sorrento announced the fourth patient was released from hospital following third infusion of stem cells
On Jan. 31, 2021, Sorrento Therapeutics announced additional positive results from its Phase 1b study of human allogeneic…
Researchers used patients’ cells to test gene therapy for rare eye disease
On Jan. 28, 2021, scientists at the National Eye Institute (NEI) have developed a promising gene therapy strategy…
CDC study showed 2019-20 flu vaccine effectively prevented hospitalizations and emergency visits in children
On Jan. 27, 2021, a U.S. Centers for Disease Control and Prevention (CDC) study found that the 2019-2020…
Just – Evotec Biologics expanded contract with Department of Defense for manufacturing of monoclonal antibodies
On Jan. 27, 2021, Evotec announced that the U.S. Department of Defense (DOD) awarded its Seattle, Washington-based subsidiary,…
WHO recommended follow-up care, low-dose anticoagulants for COVID-19 patients
On Jan. 26, 2021, WHO recommends that patients who have COVID-19 – both confirmed and suspected – should…
Sorrento announced positive preliminary results of phase 1b study of COVI-MSC for treatment of ICU COVID-19 patients
On Jan. 26, 2021, Sorrento Therapeutics announced positive preliminary results from its Phase 1b study of human allogeneic…
Regeneron reported positive data with REGEN-COV antibody cocktail as passive vaccine to prevent COVID-19
On Jan. 26, 2021, Regeneron announced positive initial results from an ongoing Phase 3 clinical trial evaluating REGEN-COV…